

Cerecin Announces Presentations of *Tricaprilin* Data at CTAD 2020

Colorado, USA. 04 November 2020 – Cerecin, a biopharmaceutical company focused on the development of drugs for neurological disorders, announces the presentation of four posters on clinical trials of its lead investigational compound, *tricaprilin* (CER-0001). *Tricaprilin* is a structured lipid designed to induce ketosis, a biological state characterized by increased production of ketone bodies. Cerecin's research centers on this metabolic pathway as a potential mechanism of action to influence brain energy metabolism in patients with Alzheimer's.

The four posters are presented at Clinical Trials for Alzheimer's Disease (CTAD 2020), being held virtually from today, November 4 until November 7, 2020. CTAD is now in its 13th year and brings together worldwide leaders to discuss developments in the treatment of AD.

Dr Judith Walker, Cerecin's Chief Medical Officer said "We are delighted to share the progress that we have made in the clinical trials with *tricaprilin* over the last several years, as well as our future plans, with the scientific community at CTAD 2020. This is a great platform for discussion of clinical trials in AD and includes global leaders working towards one common goal of finding a cure for AD."

Details of the abstracts being presented are as follows:

Poster Number: P17

Title: Administering tricaprilin after a meal optimises bioavailability and minimises adverse events

Authors: Judith Walker, Lilian Chow and Bruce Morimoto

Poster Number: P18

Title: Novel formulation AC-SD-03 of tricaprilin leads to excellent PK and safety in doses of up to 30g BID

Authors: Lilian Chow, Lars Nelleman, Bruce Morimoto, Judith Walker

Poster Number: P19

Title: An evidence-based risk-mitigation approach to study design in APOE4(-) mild to moderate AD

Authors: Judith Walker, Lars Nelleman, Bruce Morimoto, Lilian Chow

Poster Number: P20

Title: Tricaprilin Shows Similar PK, Safety and Tolerability in Caucasians and Asians

Authors: Bruce Morimoto, Lars Nelleman, Lilian Chow, Judith Walker

The abstracts and posters will be available to registered participants online on CTAD's website from November 4, 2020.

About *tricaprilin* (CER-0001)

Tricaprilin, also known as CER-0001, is a specific, structured, medium-chain triglyceride that Cerecin is developing to treat a range of neurological indications including Alzheimer's disease, migraine and infantile spasms. *Tricaprilin* is a ketogenic compound that is being studied to leverage the numerous actions of ketone bodies on brain metabolism, inflammation

and neurodegeneration. Cerecin's tricaprilin is formulated in a proprietary formula to optimize bioavailability, PK and tolerability. Tricaprilin has been extensively studied in Phase 2a, 2b and imaging studies and has shown promising effects in subjects with mild-to-moderate Alzheimer's disease who are non-carriers of the APOE4 allele. The safety and efficacy of tricaprilin will be further studied in future clinical trials.

About Alzheimer's disease

Alzheimer's disease is a complex, age-associated, progressive neurodegenerative disease and the most common form of dementia. There is currently no cure and only a few approved treatments. According to a report published by Alzheimer's Disease International, the number of people living with dementia globally will increase from close to 50 million in 2017 to 131.5 million in 2050.

About Cerecin

Cerecin is a biopharmaceutical company focused on the discovery and development of drugs to treat diseases of the brain. Cerecin's development program leverages its extensive experience in lipid science to explore the potential therapeutic benefits of ketogenic compounds. Cerecin is led by an expert executive management team with strong global expertise in central nervous system drug development. The company is supported by two partners, Nestlé and Wilmar, one of the world's leading manufacturers and traders of fatty acids and lipids. Bringing together the deep industry expertise of its leadership team, and a highly differentiated drug development program, Cerecin is becoming a global leader in neurology therapeutics.

For further information, please contact:

Thomas Harding/Khushboo Tanna

cerecin@spurwingcomms.com

© 2020 Cerecin AC-20-893 11/20

This press release contains "forward-looking statements" under applicable securities laws that are based on the current expectations and beliefs of Cerecin. All statements, except for statements of historical fact, are statements that could be deemed forward-looking statements, including but not limited to: (i) the projected financial performance of the Company; (ii) the expected development of the Company's business, projects, drug development programs and joint ventures; (iii) execution of the Company's vision and growth strategy, including with respect to future growth; and (vi) new developments with respect to the Company's projects that are currently underway, in development or otherwise under consideration. These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from projections of future performance or any result that may be expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this press release are based upon what management of Cerecin believes are reasonable assumptions, there can be no assurance or guarantee that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Cerecin undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.